Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (April 2024)
33 slides from Century Therapeutics's investor presentation, Apr 11, 2024
Slide 1: Corporate Overview April 2024
Corporate OverviewApril 2024
Slide 2: Forward-looking statements
2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical fact
Slide 3: Building an industry-leading, next-generation allogeneic iPSC-derived cell therapy platform
3Century Therapeutics: Building an industry-leading, next-generation allogeneic iPSC-derived cell therapy platformLIMITLESS POTENTIAL PRECISION DESIGN ENDURING IMPACT Foundational investments in iPSC technology, genetic editing, protein engineering, and manufacturingProgressing differentiated clinic
Slide 4: Overview of Foundational Platform Technologies
Overview of Foundational Platform Technologies
Slide 5: Century's singular focus: best-in-class iPSC-derived cell therapies
5 Century’s singular focus: To deliver best - in - class iPSC - derived cell therapies Century platform enables the incorporation of critical features we b elieve can only be realized via iPSC - derived cell therapies Infinite replicative capacity at the iPSC stage enables potentially unlimited geno
Slide 6: Next-generation allogeneic iPSC technology platform: versatility and unprecedented control
6 Century’s next - generation allogeneic iPSC technology platform: Versatility and unprecedented control Rapid Integration of major advances in product functionality and manufacturability iPSC iT cell iNK cell SINGLE CELL CLONING POST GENE EDITING AND CHARACTERIZATION DIFFERENTIATION Consistency Yie
Slide 7: Precision CRISPR MAD7 mediated sequential gene editing of iPSC cells
7 Precision CRISPR MAD7 mediated sequential gene editing of iPSC cells generates uniform product candidates Multiple gene edits (KO/KI) iPSC bank Engineered iPSC Master Cell Bank (MCB) Sequential selection steps iSPC Precision Engineering CRISPR - mediated HDR (MAD 7) Advantages of Century’s Platfor
Slide 8: Allo-Evasion edits + repeat dosing = potential greater durability
8 Allo - Evasion TM edits + repeat dosing = potential greater durability Potential to drive durable responses with engineering to resist immune rejection Next - wave of allogeneic cell therapies must solve for challenge of rejection With Allo - Evasion TM engineering Without Allo - Evasion TM engine
Slide 9: Advancing our leadership in Allo-Evasion technology
9 Advancing our leadership in Allo - Evasion TM technology Continuous improvement in holistic immune protection designed to overcome major pathways of host vs. graft rejection Allo - Evasion TM 1.0 Allo - Evasion TM 3.0 Allo - Evasion TM 5.0 b 2M KO (HLA - I) CIITA KO (HLA - II) CD8 + T Cell CD4 + T
Slide 10: Foundational investments in iPSC manufacturing
10 Foundational investments in iPSC manufacturing Established in - house manufacturing Developing fit - for - purpose products • Century 53,000 ft 2 GMP facility • Designed to produce multiple immune cell types • Accelerates learnings and enables faster product iteration • Two sites (FCDI GMP manufa
Slide 11: Therapeutics
THERAPEUTICS
Slide 12: Newly expanded and diversified pipeline
12 Newly expanded and diversified pipeline Product candidates spanning cell types and targets in cancer and autoimmune and inflammatory diseases Clinical Product iPSC Platform Targets Indications Research IND - Enabling P1 P2 P3 Collaborator / Origin Autoimmune and Inflammatory Diseases CNTY - 101 i
Slide 13: CNTY-Clinical Programs
CNTY - 101 Clinical Programs
Slide 14: CNTY-101: Differentiated next-gen CD19 targeted product
14 CNTY - 101: Differentiated next - gen CD19 targeted product Only cell therapy with six precision gene edits currently in the clinic Delivering on our vision to change the cell therapy treatment paradigm • Goal to improve durability, tolerability and ease of outpatient administration • Potential t
Slide 15: CNTY-101 in relapsed/refractory B-cell lymphomas: durable responses via repeat dosing
15 CNTY - 101 in relapsed/refractory B - cell lymphomas Aim : To deliver durable responses via repeat dosing facilitated by Allo - Evasion TM and extending the period of pharmacologic pressure on tumor cells R/R: Relapsed or Refractory, NHL: Non - Hodgkin Lymphoma, CAR - T: Chimeric Antigen Receptor
Slide 16: CNTY-101: ELiPSE-1 Phase 1 BOIN design
16 CNTY - 101: ELiPSE - 1 (NCT05336409) Phase 1 BOIN design 1 Standard lymphodepletion regimen: Fludarabine (30 mg/m2/d) and cyclophosphamide IV (300 mg/m2/d) for 3 days 2 Subjects who are assessed as stable disease or better may receive additional cycles of CNTY - 101 BOIN: Bayesian Optimal Interva
Slide 17: ELiPSE-1 enrolled heavily pretreated patients
17 ELiPSE - 1 enrolled heavily pretreated patients Baseline characteristics Patients treated 7 Median age (range) 68 (60 - 72) Prior therapy Median # of prior therapies (range) 4 (2 - 6) Prior CD - 19 - targeted CAR T - cell therapy 3 a (43%) Disease characteristics Aggressive histology 5 (71%) Refr
Slide 18: ELiPSE-1: Favorable initial safety profile
18 ELiPSE - 1: Favorable initial safety profile *Data cutoff date of November 13, 2023; represents data verified post data cut a. CAR T manufacturing failure COHORT PATIENT DISEASE HISTORY TREATMENT SAFETY Indication Prior Lines Therapy Prior CAR T? Relapse or Refractory to Last Line Dose Cycles Com
Slide 19: ELiPSE-1: Early evidence of anti-lymphoma activity at lowest dose levels
19 ELiPSE - 1: Early evidence of anti - lymphoma activity at lowest dose levels *Data cutoff date of November 13, 2023; represents data verified post data cut a. CAR T manufacturing failure COHORT PATIENT DISEASE HISTORY TREATMENT SAFETY RESPONSE Indication Prior Lines Therapy Prior CAR T? Relapse o
Slide 20: ASH case study: durable complete response
20 ASH case study: Dose level 1 patient with 6 - month durable complete response ^ *Data cutoff date of November 13, 2023; represents data verified post data cut ^Patient subsequently progressed Ramachandran, et al. 2023 ASH Annual Conference Multiple Doses of CNTY - 101, an iPSC - Derived Allogenei
Slide 21: ASH case study: early evidence of anti-lymphoma activity
21 ^Patient subsequently progressed Ramachandran, et al. 2023 ASH Annual Conference ASH case study: Early evidence of anti - lymphoma activity with durable 6 - month complete response ^ Baseline Post - initial dose (Day 28)
Slide 22: Allo-Evasion edits + repeat dosing without the need for lymphodepletion
22 Allo - Evasion TM edits + repeat dosing without the need for LD With Allo - Evasion TM engineering Without Allo - Evasion TM engineering Allo - Evasion TM enables repeat dosing without the need for continued lymphodepletion Initial clinical evidence indicates no sign of allo - rejection for CNTY
Slide 23: Summary of ELiPSE-1 data
23 Summary of ELiPSE - 1 data Cohorts of 3 billion cells/1 monthly dose and 300 million/weekly x 3 doses are open; Additional clinical data expected in mid - 2024 Heavily pretreated and refractory patient population treated in first - in - human dose escalation trial Favorable safety profile; can b
Slide 24: Key differentiators of CNTY-101 in autoimmune disease treatment
24 Key differentiators of CNTY - 101 in autoimmune disease treatment CNTY - 101: CD - 19 targeted iNK cell therapy with 6 precision gene edits including Allo - Evasion TM technology • Currently being studied in Ph1 ELiPSE - 1 trial in R/R NHL • Ph1 CALiPSO - 1 trial in SLE initiating in H1 2024 Key
Slide 25: CNTY-101: Potential to drive B-cell depletion with tighter control over drug exposure
25 CNTY - 101: Potential to drive B - cell depletion with tighter control over drug exposure More potent than primary CAR - T at B - cell killing in pre - clinical comparison CNTY - 101 more potent than primary CAR - T cells at B - cell killing at 24 hours in pre - clinical comparison Isolated B cel
Slide 26: Opportunity in systemic lupus erythematosus to improve long-term disease control
26 Opportunity in systemic lupus erythematosus to improve long - term disease control 1. Tian J, et al. Ann Rheum Dis 2023;82:351 – 356 http://dx.doi.org/10.1136/ard - 2022 - 223035 2. Mackensen A, et al.. Nature Medicine 2022 28:10 (2124 - 2132) https://doi.org/10.1038/s41591 - 022 - 02017 - 5 CNS:
Slide 27: CNTY-101: CALiPSO-1 systemic lupus erythematosus Phase 1 study
27 CNTY - 101: CALiPSO - 1 systemic lupus erythematosus Phase 1 study Inclusion: • Patients with moderate to severe SLE after 2+ standard immunosuppressive therapies Endpoints: • Key endpoints: Safety, SLE manifestations per SLEDAI, LLDAS, DORIS • Translational Endpoints: B - cell depletion, auto -
Slide 28: Century Therapeutics
CENTURY THERAPEUTICS
Slide 29: CNTY-102: next generation γδ iT and iNK cell platform
29 CNTY - 102: Leveraging the next generation γδ iT and iNK cell platform designed to deliver best - in - class potential Designed to address factors that limit durability of cell therapy in B - cell malignancies • i NK and γδ iT cells have distinct properties that provide optionality in the face of
Slide 30: CNTY-107: First in class Nectin-4 targeted γδ iT cell therapy
30 CNTY - 107: First in class Nectin - 4 targeted γδ iT cell therapy Leveraging the power of the γδ iT cell platform for solid tumors Nectin - 4 has been validated by ADC approaches • Opportunity to address multiple Nectin - 4 positive solid tumors — Potential indications include bladder, breast, pa
Slide 31: Century Therapeutics
CENTURY THERAPEUTICS
Slide 32: Multiple near-term catalysts and cash resources
32 MULTIPLE NEAR - TERM CATALYSTS CASH RESOURCES Advancing next - generation iPSC - derived allogeneic NK and T cell therapy candidates for the treatment of cancer and autoimmunity Phase 1 ELiPSE - 1 trial of CNTY - 101 in B - cell malignancies • Additional data expected in mid - 2024 Phase 1 trial
Slide 33: Building an industry-leading, next-generation allogeneic iPSC-derived cell therapy platform
33Century Therapeutics: Building an industry-leading, next-generation allogeneic iPSC-derived cell therapy platformLIMITLESS POTENTIAL PRECISION DESIGN ENDURING IMPACT Foundational investments in iPSC technology, genetic editing, protein engineering, and manufacturingProgressing differentiated clini
Century Therapeutics — Investor Presentation (April 2024) on 6ix